BNIP3 plays a role in hypoxic cell death in human epithelial cells that is inhibited by growth factors EGF and IGF

被引:180
作者
Kothari, S
Cizeau, J
McMillan-Ward, E
Israels, SJ
Bailes, M
Ens, K
Kirshenbaum, LA
Gibson, SB
机构
[1] Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB, Canada
[2] St Boniface Gen Hosp, Res Ctr, Inst Cardiovasc Sci, Winnipeg, MB R2H 2A6, Canada
[3] Univ Manitoba, Fac Med, Dept Physiol, Winnipeg, MB, Canada
[4] Univ Manitoba, Fac Med, Dept Biochem & Med Genet, Winnipeg, MB, Canada
基金
加拿大健康研究院;
关键词
hypoxia; cell death; tumor; BNIP3; EGF; IGF;
D O I
10.1038/sj.onc.1206666
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Hypoxic regions within solid tumors are often resistant to chemotherapy and radiation. BNIP3 (Bcl-2/E1B 19 kDa interacting protein) is a proapoptotic member of the Bcl-2 family that is expressed in hypoxic regions of tumors. During hypoxia, BNIP3 expression is increased in many cell types and upon forced overexpression BNIP3 induces cell death. Herein, we have demonstrated that blockage of hypoxia-induced BNIP3 expression using antisense oligonucleotides against BNIP3 or blockage of BNIP3 function through expression of a mutant form of BNIP3 inhibits hypoxia-induced cell death in human embryonic kidney 293 cells. We have also determined that hypoxia-mediated BNIP3 expression is regulated by the transcription factor, hypoxia-inducible factor-1alpha (HIF-1alpha) in human epithelial cell lines. Furthermore, HIF-1alpha directly binds to a consensus HIF-1alpha-responsive element (HRE) in the human BNIP3 promoter that upon mutation of this HRE site eliminates the hypoxic responsiveness of the promoter. Since BNIP3 is expressed in hypoxic regions of tumors but fails to induce cell death, we determined whether growth factors block BNIP3-induced cell death. Treatment of the breast cancer cell line MCF-7 cells with epidermal growth factor (EGF) or insulin-like growth factor effectively protected these cells from BNIP3-induced cell death. Furthermore, inhibiting EGF receptor signaling using antibodies against ErbB2 (Herceptin) resulted in increased hypoxia-induced cell death in MCF-7 cells. Taken together, BNIP3 plays a role in hypoxia-induced cell death in human epithelial cells that could be circumvented by growth factor signaling.
引用
收藏
页码:4734 / 4744
页数:11
相关论文
共 45 条
[1]   Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia [J].
Bruick, RK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (16) :9082-9087
[2]  
Burris HA, 2000, SEMIN ONCOL, V27, P19
[3]   Hypoxia regulation of gene transcription [J].
Caro, J .
HIGH ALTITUDE MEDICINE & BIOLOGY, 2001, 2 (02) :145-154
[4]   Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3 [J].
Chapman, RS ;
Lourenco, PC ;
Tonner, E ;
Elint, DJ ;
Selbert, S ;
Takeda, K ;
Akira, S ;
Clarke, AR ;
Watson, CJ .
GENES & DEVELOPMENT, 1999, 13 (19) :2604-2616
[5]   The E1B 19K Bcl-2-binding protein Nip3 is a dimeric mitochondrial protein that activates apoptosis [J].
Chen, G ;
Ray, R ;
Dubik, D ;
Shi, LF ;
Cizeau, J ;
Bleackley, RC ;
Saxena, S ;
Gietz, RD ;
Greenberg, AH .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (12) :1975-1983
[6]   Nix and Nip3 form a subfamily of pro-apoptotic mitochondrial proteins [J].
Chen, G ;
Cizeau, J ;
Velde, CV ;
Park, JH ;
Bozek, G ;
Bolton, J ;
Shi, L ;
Dubik, D ;
Greenberg, A .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (01) :7-10
[7]   The C-elegans orthologue ceBNIP3 interacts with CED-9 and CED-3 but kills through a BH3-and caspase-independent mechanism [J].
Cizeau, J ;
Ray, R ;
Chen, G ;
Gietz, RD ;
Greenberg, AH .
ONCOGENE, 2000, 19 (48) :5453-5463
[8]  
Clawson TF, 1999, BIOL SIGNAL RECEPT, V8, P281
[9]   Cloning of BNIP3h, a member of proapoptotic BNIP3 family genes [J].
Farooq, M ;
Kim, Y ;
Im, S ;
Chung, E ;
Hwang, S ;
Sohn, M ;
Kim, M ;
Kim, J .
EXPERIMENTAL AND MOLECULAR MEDICINE, 2001, 33 (03) :169-173
[10]   Insulin-like growth factors and cancer [J].
Fürstenberger, G ;
Senn, HJ .
LANCET ONCOLOGY, 2002, 3 (05) :298-302